• FDA approves selexipag for IV use in adults with PAH

    1 month ago - By Healio

    The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy.
    Selexipag for IV use will allow patients to avoid short-term interruptions and stay on their therapy, as uninterrupted treatment is important for patients with PAH, according to a company press release.
    Selexipag tablets were previously approved by the FDA in 2015 to delay PAH progression and reduce risk for hospitalization.
    “Today marks an important day for patients who rely on Uptravi, as this new
    Read more ...

     

  • FDA approves Shingrix for prevention of shingles in immunocompromised adults

    FDA approves Shingrix for prevention of shingles in immunocompromised adults

    1 month ago - By Healio

    The FDA this week approved Shingrix for the prevention of shingles in immunocompromised adults, GlaxoSmithKline announced.
    Shingrix , is a nonlive, recombinant sub-unit adjuvanted vaccine that was initially approved by the FDA in 2017 for the prevention of shingles in adults aged 50 years or older.
    The vaccine, which is administered intramuscularly in two doses, is now approved for adults aged 18 years or older who are or will be at an increased risk for shingles because of immunodeficiency or immunosuppression caused by known disease or therapy, GlaxoSmithKline
    Read more ...